PMID- 24778045
OWN - NLM
STAT- MEDLINE
DCOM- 20140623
LR  - 20151119
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 34
IP  - 5
DP  - 2014 May
TI  - HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and 
      base of tongue cancer.
PG  - 2369-75
AB  - BACKGROUND/AIM: Patients with human papillomavirus (HPV)-positive tonsillar and 
      base of tongue cancer have a better outcome than those with corresponding 
      HPV-negative tumors (80% vs. 40% 5-year disease free survival with conventional 
      radiotherapy). They should not all need chemoradiotherapy, but before tapering 
      treatment, more markers are needed to predict treatment response. In the present 
      study, human leukocyte antigen (HLA) - HLA-A*02 was analyzed with HPV as a 
      prognostic factor for tonsillar and base of tongue cancer. PATIENTS AND METHODS: 
      Pre-treatment biopsies, previously tested for HPV DNA, from 425 patients 
      diagnosed with tonsillar and base of tongue cancer between 2000-2009 at the 
      Karolinska University Hospital were examined for HLA-A*02. RESULTS: HLA-A*02 was 
      present in 144/305 (47.2%) of the HPV-positive and 63/120 (52.8%) of the 
      HPV-negative tumours. Among 383 patients treated with curative intent, absence of 
      HLA-A*02 was correlated with increased disease-free survival in the HPV-positive 
      (p=0.016), but not in the HPV-negative group. CONCLUSION: Absence of HLA-A*02 
      correlated with better disease-free survival for patients with HPV-positive 
      tonsillar and base of tongue cancer.
FAU - Tertipis, Nikolaos
AU  - Tertipis N
AD  - Department of Oncology-Pathology, Karolinska Institutet, Cancer Center 
      Karolinska, R8:01 Karolinska University Hospital, 171 76 Stockholm, Sweden. 
      Tina.Dalianis@ki.se.
FAU - Villabona, Lisa
AU  - Villabona L
FAU - Nordfors, Cecilia
AU  - Nordfors C
FAU - Nasman, Anders
AU  - Nasman A
FAU - Ramqvist, Torbjorn
AU  - Ramqvist T
FAU - Vlastos, Andrea
AU  - Vlastos A
FAU - Masucci, Giuseppe
AU  - Masucci G
FAU - Dalianis, Tina
AU  - Dalianis T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-A*02 antigen)
RN  - 0 (HLA-A2 Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis/immunology
MH  - Carcinoma, Squamous Cell/*immunology/mortality/virology
MH  - Disease-Free Survival
MH  - Female
MH  - HLA-A2 Antigen/*biosynthesis/genetics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Papillomavirus Infections/complications/immunology/mortality
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Tongue Neoplasms/*immunology/mortality/virology
MH  - Tonsillar Neoplasms/*immunology/mortality/virology
OTO - NOTNLM
OT  - HLA-A*02 genotype
OT  - base of tongue cancer
OT  - clinical outcome
OT  - human papillomavirus (HPV) oropharyngeal squamous cell carcinoma
OT  - tonsillar cancer
EDAT- 2014/04/30 06:00
MHDA- 2014/06/24 06:00
CRDT- 2014/04/30 06:00
PHST- 2014/04/30 06:00 [entrez]
PHST- 2014/04/30 06:00 [pubmed]
PHST- 2014/06/24 06:00 [medline]
AID - 34/5/2369 [pii]
PST - ppublish
SO  - Anticancer Res. 2014 May;34(5):2369-75.